SHPH net incomeQ2 2026-$3.15M
SHPH net income was -$3.15M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.71M a year earlier. For the full fiscal 2025 it was -$11.72M, compared with -$9.14M in fiscal 2024.
Shuttle Pharmaceuticals Holdings Inc. (SHPH) financials
For the twelve months ended Jun 30, 2026, Shuttle Pharmaceuticals Holdings Inc. reported -$10.26M of net income.
- Net income, TTM
- -$10.26M
- Cash
- $90.2K
- Market cap
- $25.4M
FY2021FY2025
SHPH revenue and earnings growth
SHPH EPSQ2 2026-$3.10
SHPH diluted EPS was -$3.10 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$71.60.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Research and development | $4.05M | $3.62M | $3.52M | $1.05M | $1.02M |
| Selling, general and admin | $5.67M | $1.39M | $1.05M | $473.7K | $36.5K |
| Operating income | -$11.92M | -$7.70M | -$5.89M | -$2.34M | -$1.74M |
| Pre-tax income | - | - | -$6.59M | -$5.00M | -$1.15M |
| Net income | -$11.72M | -$9.14M | -$6.59M | -$5.00M | -$1.15M |
| EPS, basic | -$71.60 | -$796.50 | -$882.50 | -$1260.00 | -$240.00 |
| EPS, diluted | -$71.60 | -$826.00 | -$882.50 | -$1260.00 | - |
| Diluted shares | 163,792.6 | 11,549.3 | 7,465.1 | 5,350.968 | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $334.0K | $1.92M | $2.58M | $8.42M | $504.7K |
| Short-term investments | - | - | $2.89M | - | - |
| Current assets | $502.9K | $2.21M | $5.59M | $8.58M | $509.6K |
| Total assets | $10.48M | $2.51M | $5.95M | $8.65M | $651.6K |
| Current liabilities | $7.97M | $1.53M | $1.04M | $975.7K | $2.22M |
| Long-term debt | - | - | $135.1K | - | - |
| Total debt | - | $0 | $135.1K | - | $91.0K |
| Total liabilities | $8.22M | $1.80M | $1.90M | $975.7K | $2.28M |
| Shareholders' equity | $2.25M | $709.2K | $4.06M | $7.68M | -$1.76M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.48M | -$7.33M | -$5.58M | -$2.67M | -$300.3K |
| Capital expenditures | - | - | $19.0K | - | - |
| Free cash flow | - | - | -$5.60M | - | - |
| Investing cash flow | -$3.06M | $2.92M | -$2.83M | - | - |
| Financing cash flow | $10.95M | $3.76M | $2.57M | $10.58M | $687.9K |
| Stock-based compensation | $933.0K | $259.7K | $182.0K | $237.5K | $910.1K |
| Depreciation and amortization | $290.1K | $5.5K | - | - | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $55.7K | $267.2K | $511.9K | $943.5K | $1.03M | $1.57M | $986.4K | $1.40M | $645.7K | $586.1K | $710.4K | $1.05M |
| Selling, general and admin | $1.98M | $1.16M | $1.84M | $886.1K | $2.35M | $596.9K | $429.1K | $329.0K | $310.0K | $324.6K | $316.7K | $265.6K |
| Operating income | -$3.95M | -$2.22M | -$2.79M | -$2.27M | -$3.91M | -$2.95M | -$1.78M | -$3.05M | -$1.48M | -$1.38M | -$1.28M | -$1.60M |
| Interest expense | - | - | - | - | - | - | - | - | - | - | - | $623.5K |
| Pre-tax income | - | - | - | - | - | - | - | - | - | - | -$1.64M | -$1.78M |
| Net income | -$3.15M | -$2.15M | -$2.61M | -$2.35M | -$3.71M | -$3.05M | -$1.60M | -$3.78M | -$2.03M | -$1.73M | -$1.64M | -$1.79M |
| EPS, basic | -$3.10 | -$4.30 | - | -$10.50 | -$32.91 | -$76.00 | - | -$398.30 | -$241.20 | -$207.50 | -$205.00 | -$227.50 |
| EPS, diluted | -$3.10 | -$4.30 | - | -$10.50 | -$32.91 | -$76.00 | - | -$398.30 | -$241.20 | -$207.50 | -$205.00 | -$227.50 |
| Diluted shares | 1.0M | 503,156.9 | - | 223,365 | 112,611 | 40,195.7 | - | 9,500.4 | 8,419.7 | 8,302.98 | - | 7,879.616 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $90.2K | $1.09M | $334.0K | $2.09M | $4.82M | $4.51M | $1.92M | $156.7K | $695.6K | $1.40M | $2.58M | $3.89M |
| Short-term investments | - | - | - | - | - | - | - | - | $1.64M | $2.79M | $2.89M | $2.92M |
| Current assets | $396.4K | $2.46M | $502.9K | $3.27M | $5.19M | $4.96M | $2.21M | $361.4K | $2.49M | $4.41M | $5.59M | $7.00M |
| Total assets | $22.81M | $11.81M | $10.48M | $3.54M | $5.50M | $5.31M | $2.51M | $673.6K | $2.81M | $4.75M | $5.95M | $7.38M |
| Current liabilities | $3.48M | $8.31M | $7.97M | $1.96M | $1.69M | $1.78M | $1.53M | $1.66M | $1.38M | $1.49M | $1.04M | $810.4K |
| Long-term debt | - | - | - | - | - | - | - | - | - | - | $135.1K | $134.4K |
| Total debt | - | - | - | - | - | $0 | $0 | - | - | - | $135.1K | $134.4K |
| Total liabilities | $3.63M | $8.46M | $8.22M | $2.15M | $1.90M | $2.02M | $1.80M | $1.99M | $2.01M | $1.99M | $1.90M | $1.77M |
| Shareholders' equity | $19.18M | $3.35M | $2.25M | $1.39M | $3.61M | $3.29M | $709.2K | -$1.32M | $801.4K | $2.76M | $4.06M | $5.61M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$567.6K | -$2.42M | -$973.0K | -$2.63M | -$3.36M | -$2.53M | -$2.69M | -$2.00M | -$1.40M | -$1.24M | -$1.06M | -$1.53M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | $0 | - |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | -$1.06M | - |
| Investing cash flow | -$5.43M | -$36.0K | - | - | - | - | $0 | $1.66M | $1.16M | $101.3K | $87.0K | -$25.9K |
| Financing cash flow | $5.00M | $3.21M | $2.27M | -$96.4K | $3.66M | $5.12M | $4.45M | -$196.8K | -$461.7K | -$40.0K | -$334.4K | $0 |
| Stock-based compensation | -$7.5K | $35.0K | $214.8K | $134.3K | $46.9K | $537.0K | $31.9K | $45.3K | $71.2K | $111.4K | $86.5K | $37.6K |
| Depreciation and amortization | $633.5K | $633.3K | - | - | -$979 | $1.0K | - | - | - | - | - | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.11 | 0.30 | 0.06 | 1.66 | 3.07 | 2.78 | 1.44 | 0.22 | 1.79 | 2.96 | 5.37 | 8.63 |
| Debt to equity | - | - | - | - | - | 0.00 | 0.00 | - | - | - | 0.03 | 0.02 |
Source: XBRL data Shuttle Pharmaceuticals Holdings Inc. files with the SEC, latest filing dated Sep 24, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-8, first reported Sep 4, 2024; 1-for-25, first reported Aug 13, 2025; 1-for-10, first reported Sep 24, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
SHPH peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| SHPH | - | - | -$10.26M | - | $25.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
SHPH FAQ
4 questionsIs SHPH profitable?
No. Shuttle Pharmaceuticals Holdings Inc. reported a net loss of $10.26M for the twelve months ended Jun 30, 2026.How much cash and debt does SHPH have?
Shuttle Pharmaceuticals Holdings Inc. reported $90.2K in cash and cash equivalents on its most recent balance sheet in SEC filings.When did SHPH last report financial results?
The latest statements here come from Shuttle Pharmaceuticals Holdings Inc.'s 10-Q filed on Sep 24, 2026, covering the period ended Jun 30, 2026.Where does this SHPH financial data come from?
Quantisnow builds these statements from the structured XBRL data Shuttle Pharmaceuticals Holdings Inc. files with the SEC. It is provided for information only and is not investment advice.